MX371021B - Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables. - Google Patents
Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.Info
- Publication number
- MX371021B MX371021B MX2016002612A MX2016002612A MX371021B MX 371021 B MX371021 B MX 371021B MX 2016002612 A MX2016002612 A MX 2016002612A MX 2016002612 A MX2016002612 A MX 2016002612A MX 371021 B MX371021 B MX 371021B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- saroglitazar
- present
- polymorphic form
- pyrrole derivative
- Prior art date
Links
- 150000003233 pyrroles Chemical class 0.000 title 1
- 229950006544 saroglitazar Drugs 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- UJYFZCVPOSZDMK-YPPDDXJESA-L magnesium (2S)-2-ethoxy-3-[4-[2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethoxy]phenyl]propanoate Chemical compound [Mg++].CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C([O-])=O.CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C([O-])=O UJYFZCVPOSZDMK-YPPDDXJESA-L 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2828MU2013 IN2013MU02828A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2013-08-29 | 2014-08-28 | |
| PCT/IN2014/000551 WO2015029066A1 (en) | 2013-08-29 | 2014-08-28 | Polymorphic form of pyrrole derivative and intermediate thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016002612A MX2016002612A (es) | 2016-10-04 |
| MX371021B true MX371021B (es) | 2020-01-13 |
Family
ID=51947417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002612A MX371021B (es) | 2013-08-29 | 2014-08-28 | Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables. |
Country Status (7)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2670486T3 (pl) | 2011-01-31 | 2016-08-31 | Cadila Healthcare Ltd | Leczenie lipodystrofii |
| EP2988736A1 (en) | 2013-04-22 | 2016-03-02 | Cadila Healthcare Limited | A novel composition for nonalcoholic fatty liver disease (nafld) |
| PH12015502667B1 (en) | 2013-05-30 | 2023-10-18 | Zydus Lifesciences Ltd | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
| TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
| IN2013MU02470A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| IN2013MU02905A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2013-09-06 | 2015-07-03 | Cadila Healthcare Ltd | |
| US20180125816A1 (en) * | 2015-05-11 | 2018-05-10 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| JP6840853B2 (ja) | 2016-12-09 | 2021-03-10 | カディラ・ヘルスケア・リミテッド | 原発性胆汁性胆管炎の治療 |
| MX2020008066A (es) * | 2018-01-30 | 2020-09-25 | Kainos Medicine Inc | Formas de sal de compuesto organico. |
| US20220169603A1 (en) * | 2019-03-11 | 2022-06-02 | Cadila Healthcare Ltd. | Novel salts, crystalline forms and premix of hypolipidemic agent |
| US12201611B2 (en) * | 2020-07-24 | 2025-01-21 | Zydus Lifesciences Limited | Composition comprising high purity pyrrole derivative and method for preparation thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713494B1 (en) * | 1996-08-28 | 2004-03-30 | Eli Lilly And Company | Amorphous benzothiophenes, methods of preparation and methods of use |
| KR100435315B1 (ko) * | 1998-01-07 | 2004-06-10 | 메이지 세이카 가부시키가이샤 | 결정학적으로 안정된 비정질 세파로스포린 조성물과 그제조 방법 |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| US6514995B1 (en) | 2000-09-25 | 2003-02-04 | Advanced Research And Technology Institute, Inc. | Enediyne compounds and methods related thereto |
| US6627760B1 (en) * | 2001-06-25 | 2003-09-30 | Astrazeneca Ab | Amorphous compound |
| US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| WO2004000823A1 (en) * | 2002-06-21 | 2003-12-31 | Dr. Reddy's Laboratories Limited | Amorphous form of(-)-}2-}4-}(4-chlorophenyl)-phenyl methyl}-1-piperazinyl] ethoxy] acetic acid dihydrochloride (levocetririzine dihydrochloride) |
| HRP20020614A2 (en) * | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
| EP1587792B1 (en) * | 2003-01-27 | 2014-08-27 | Hanmi Science Co., Ltd. | Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof |
| US20040266787A1 (en) * | 2003-03-25 | 2004-12-30 | Dr. Reddy's Laboratories Limited | Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof |
| EP1660081A1 (en) * | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
| AR052918A1 (es) * | 2005-02-25 | 2007-04-11 | Recordati Ireland Ltd | Clorhidrato de lercanidipina amorfo |
| US10532028B2 (en) * | 2005-07-28 | 2020-01-14 | Isp Investments Llc | Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced |
| US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
| PL2670486T3 (pl) | 2011-01-31 | 2016-08-31 | Cadila Healthcare Ltd | Leczenie lipodystrofii |
| PH12015502667B1 (en) | 2013-05-30 | 2023-10-18 | Zydus Lifesciences Ltd | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
-
2014
- 2014-08-28 US US14/915,457 patent/US9951009B2/en active Active
- 2014-08-28 WO PCT/IN2014/000551 patent/WO2015029066A1/en active Application Filing
- 2014-08-28 MX MX2016002612A patent/MX371021B/es active IP Right Grant
- 2014-08-28 IN IN2828MU2013 patent/IN2013MU02828A/en unknown
- 2014-08-28 EP EP14802513.3A patent/EP3039011A1/en not_active Withdrawn
-
2016
- 2016-02-29 PH PH12016500394A patent/PH12016500394A1/en unknown
- 2016-03-03 ZA ZA2016/01461A patent/ZA201601461B/en unknown
-
2018
- 2018-04-06 US US15/947,049 patent/US20180297946A1/en not_active Abandoned
- 2018-04-06 US US15/947,044 patent/US20180297945A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160207884A1 (en) | 2016-07-21 |
| ZA201601461B (en) | 2017-05-31 |
| EP3039011A1 (en) | 2016-07-06 |
| US20180297945A1 (en) | 2018-10-18 |
| IN2013MU02828A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-03 |
| PH12016500394A1 (en) | 2016-05-16 |
| WO2015029066A1 (en) | 2015-03-05 |
| US9951009B2 (en) | 2018-04-24 |
| MX2016002612A (es) | 2016-10-04 |
| US20180297946A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500394A1 (en) | Polymorphic form of pyrrole derivative and intermediate thereof | |
| MY175854A (en) | Novel quinolone derivatives | |
| IN2014MN02106A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX2015005286A (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| PH12014502605A1 (en) | Uracyl spirooxetane nucleosides | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| PH12014502040A1 (en) | Heterocyclyl compounds | |
| IN2014MN02598A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| IN2014CN04530A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| MY162397A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| IN2014MN02380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| IN2014DN08296A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| PH12016500980B1 (en) | Amide derivatives for gpr119 agonist | |
| IN2014MN02433A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO2015102017A8 (en) | Processes for the preparation of lorcaserin | |
| WO2014106826A3 (en) | Anthracycline analogue and uses thereof | |
| IN2013MU03838A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |